Intra-Cellular Therapies Inc
ITCI
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.05B
Close$
$69.66
47.2% downside
Current Fair Value
47.2% downsideOvervalued by 47.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.05 Billion |
|---|---|
| Enterprise Value | $13.76 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.72 |
| Beta | 0.46 |
| Outstanding Shares | 103,131,017 |
Return
| Return on Equity | -6.50% |
|---|---|
| Return on Assets | -5.46% |
| Return on Invested Capital | -10.05% |
Valuation & Multiples
| P/E Ratio | -183.15 |
|---|---|
| PEG | 447.61 |
| Price to Sales | 21.98 |
| Price to Book Ratio | 11.99 |
| Enterprise Value to Revenue | 20.21 |
| Enterprise Value to EBIT | -117.86 |
| Enterprise Value to Net Income | -185 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Intra-Cellular Therapies Inc
CEO: Sharon Mates